FutureMeds and Pharmaxi signed a Memorandum of Understanding to offer improved, streamlined, and more robust solutions and further strengthen the clinical research industry in Ukraine.
FutureMeds and Pharmaxi, a Ukrainian Contract Research Organization (CRO) with operations in Ukraine and Poland, signed a Memorandum of Understanding (MOU) last week.
The MOU is an important milestone for the clinical research industry in Ukraine. Signed between two significant players in the industry, the MOU aims to
Establish a framework for closer collaboration
Bring new and innovative therapies to patients in the most efficient way possible
Support and strengthen clinical research capabilities in Ukraine.
The scope of collaboration between FutureMeds and Pharmaxi includes
Working together in Ukraine and other countries of operations of both companies to speed up the delivery of high-quality data for sponsors,
Providing access to diverse patient populations,
Streamlining operational interaction, communication and cooperation.
The ultimate goal of close collaboration is to offer sponsors a more efficient and cost-effective way to conduct clinical trials in Ukraine.
“The signing of this MOU is another milestone in our industry. It not only signals all the effort our respective organisations put into creating robust continuity, but it also encourages and strengthens collaboration in order to enable Sponsors to access diverse patient populations, consult highly skilled workforce and ultimately run more efficient and cost-effective conduct clinical trials in the country.”
- Ivan Vyshnyvetskyy, MD, PhD, Managing Director, FutureMeds Ukraine
The clinical research industry in Ukraine has come a long way in recent years, with significant investments in infrastructure, technology, and human resources.
The recently introduced centralised electronic health system, which already has more than 500 million electronic medical records, successfully overcame all war-related challenges. All our hospitals have their own power sources and stable internet connections. As a result of the collective effort of all stakeholders, the majority of research sites that are not in the occupied or adjacent territories continue their job as usual in ongoing trials:
Sites have all systems and capabilities in place to produce high-quality data.
Studies are monitored (on-site and remotely) by CRAs (Clinical Research Associate or Trial Monitor) and inspected by Regulatory Authorities.
Samples are shipped to neighbouring counties by land and later via air to distant destinations
The country also offers a favourable regulatory environment, with a well-established legal framework for clinical trials that support fast startup times.
About FutureMeds
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.